Seer, Inc.
A biotechnology company that helps scientists study the proteome—the full set of proteins in a body—using its Proteograph product suite, which relies on engineered nanoparticles that naturally gather proteins from blood samples. Founded in 2017 by researchers including Robert Langer, it grew out of nanoparticle work at Harvard's Brigham and Women's Hospital. The name "Seer" means one who sees, a nod to giving researchers a clearer view of proteins that were once hard to detect.
Granted 697.2K · Sold 58.2K
Granted 79.0K · Sold 21.8K
Granted 75.0K
Granted 41.0K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Farokhzad OmidCEO AND CHAIR, Director · 5 transactions | — | 5.47M | 697.2K | — | 58.2K |
| Horn David R.PRESIDENT & CFO · 4 transactions | +13.1% | 494.0K | 79.0K | — | 21.8K |
| McGuire TerranceDirector · 1 transaction | — | 406.1K | — | — | — |
| Bazarko Anthony R.Chief Commercial Officer · 1 transaction | — | 75.0K | 75.0K | — | — |
| Ro IsaacDirector · 1 transaction | — | 41.0K | 41.0K | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last year: -80.1K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.